Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Px-478, an Hif-1Α Inhibitor, Impairs Mesocar T Cell Antitumor Function in Cervical Cancer
Tahereh Soltantoye

Assistant Professor of Medical Immunology

Department Immunology

School of Medicine

Tehran University of Medical Sciences

All Documents
1. Px-478, an Hif-1Α Inhibitor, Impairs Mesocar T Cell Antitumor Function in Cervical Cancer, Frontiers in Oncology (2024)
2. Crosstalk Between Autophagy and Metabolic Regulation of (Car) T Cells: Therapeutic Implications, Frontiers in Immunology (2023)
3. Pge2-Ep2/Ep4 Signaling Elicits Mesocar T Cell Immunosuppression in Pancreatic Cancer, Frontiers in Immunology (2023)
4. The Inhibitory Receptors Pd1, Tim3, and A2ar Are Highly Expressed During Mesocar T Cell Manufacturing in Advanced Human Epithelial Ovarian Cancer, Cancer Cell International (2023)
5. Chimeric Antigen Receptor (Car) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead, Cells (2021)
6. Epigenetic Strategies to Boost Car T Cell Therapy, Molecular Therapy (2021)
7. Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors, Frontiers in Immunology (2021)
8. Development of a Novel Inhibitory Chimeric Anti-Her2 Monoclonal Antibody, Iranian Journal of Immunology (2019)
9. Differential Effects of Inhibitory and Stimulatory Anti-Her2 Monoclonal Antibodies on Akt/Erk Signaling Pathways, Asian Pacific Journal of Cancer Prevention (2018)
10. Hersintuzumab: A Novel Humanized Anti-Her2 Monoclonal Antibody Induces Potent Tumor Growth Inhibition, Investigational New Drugs (2018)
11. Epitope Mapping of Human Her2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains, Asian Pacific Journal of Cancer Prevention (2017)
12. Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro, Iranian Journal of Immunology (2017)